Simply Wall St.17d agoneutral
How Investors Are Reacting To Vertex (VRTX) FDA ALYFTREK Expansion and Evolving Pipeline StoryRecently, Vertex Pharmaceuticals reported that director Suketu Upadhyay will leave its board at the 2026 annual meeting while the US FDA approved expanded use of ALYFTREK for cystic fibrosis patients aged 6 and older. At the same time, Bank of America reaffirmed Vertex as a top large-cap biotech pick, underscoring how its cystic fibrosis cash flows are supporting a broader pipeline that now includes a rare kidney disease franchise. We’ll now examine how the FDA’s expanded ALYFTREK approval...
